BioAtla, Inc. (NASDAQ:BCAB) Short Interest Update

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 4,220,000 shares, a growth of 32.7% from the February 28th total of 3,180,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is currently 4.0 days. Currently, 9.9% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of BioAtla in a report on Monday.

BioAtla Stock Performance

Shares of NASDAQ BCAB opened at $0.35 on Monday. The company has a market capitalization of $16.78 million, a PE ratio of -0.20 and a beta of 1.19. The company’s fifty day moving average price is $0.40 and its 200 day moving average price is $1.12. BioAtla has a 1 year low of $0.24 and a 1 year high of $4.02.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. On average, equities analysts expect that BioAtla will post -1.46 EPS for the current year.

Institutional Trading of BioAtla

Institutional investors and hedge funds have recently made changes to their positions in the business. Magnus Financial Group LLC purchased a new position in shares of BioAtla during the 4th quarter valued at approximately $28,000. Two Sigma Investments LP raised its position in BioAtla by 84.0% during the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock worth $80,000 after acquiring an additional 61,725 shares during the period. Jane Street Group LLC lifted its holdings in BioAtla by 204.1% during the fourth quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock valued at $88,000 after purchasing an additional 100,204 shares in the last quarter. XTX Topco Ltd grew its position in shares of BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares during the period. Finally, Norges Bank purchased a new stake in shares of BioAtla during the fourth quarter worth about $230,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.